Navigation Links
Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
Date:8/22/2007

A nanoparticle drug delivery system designed for brain tumor therapy has shown promising tumor cell selectivity in a novel cell culture model devised by University of Nottingham scientists. The project, conducted jointly in the Schools of Pharmacy, Biomedical Sciences and Human Development, will be featured in the September issue of the Experimental Biology and Medicine.

Therapy for brain cancers is particularly difficult for a number of reasons, including getting sufficient drug to the tumor and selectivity of drug action. We are working on a number of new therapeutic approaches using nanoparticle drug delivery systems explained Dr Martin Garnett, Associate Professor of drug delivery at the School of Pharmacy, however, understanding and developing these systems requires suitable models for their evaluation.

The nanoparticles used in this study were prepared from a novel biodegradable polymer poly(glycerol adipate). The polymer has been further modified to enhance incorporation of drugs and make the nanoparticles more effective.

The interaction of tumor cells with brain cells varies between different tumors and different locations within the brain explained Dr Terence Parker, Associate Professor in the School of Biomedical Sciences. Using 3-dimensional culture models is therefore important in ensuring that the behavior of cells in culture is similar to that seen in real life.

The work was mainly carried out by graduate student Weina Meng who formulated the fluorescently labeled nanoparticles and studied them in a variety of tumor and brain cell cultures. Her early studies showed faster uptake of nanoparticles into tumor cell cultures than normal brain cell cultures grown separately. This selectivity was only seen in 3-dimensional cultures and was the driving force to develop a more complex and representative model.

Tumor cell aggregates have been used as cell culture models of cancer cells for many years. Similarly thin brain slices from newborn rats can be cultured for weeks and are an important tool in brain biology. In the cell co-culture model now reported, these two techniques have been brought together for the first time. Brain tumor cell aggregates were labeled with fluorescent iron microparticles and grown on normal newborn rat-brain tissue slices. The double cell labeling technique allowed investigation of tumor cell invasion into brain tissue by either fluorescence or electron microscopy from the same samples. Using these techniques the tumor aggregates were found to invade the brain slices in a similar manner to tumors in the body. Having developed the model then the tumor selective uptake of nanoparticles was demonstrated in the co-culture.

The collaboration on this project has been nurtured by Professor David Walker of the School of Human Development who co-founded the Childrens Brain Tumor Research Group at Nottingham. Understanding the biology of tumors is important if we are to develop effective new treatments said Professor Walker. This work demonstrates how close co-operation between disciplines can help to push forward ideas which could lead to new clinical therapies.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees with Professor Walker. Dr. Goodman stated The convergence of cancer cell biology and nanoscience, exemplified by this study, holds great promise for the future of brain tumor therapy. Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.


'/>"/>

Contact: Dr. Martin Garnett
martin.garnett@nottingham.ac.uk
44-011-595-15045
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
7. Discovery Could Lead To Novel Approaches In HIV Treatment
8. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
9. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
10. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
11. GeneNotes - A novel information management software for biologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
Breaking Biology Technology: